Royalty Pharma Community
Create a narrative
WA
Based on Analyst Price Targets
Decisive Investments And Innovations Propel Revenue And Earnings Growth Amid Healthcare Shifts
US$45.38
FV
37.9% undervalued intrinsic discount8.36%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
18 days agoauthor updated this narrative